Physician profile

Cynthia D Rivera

Forensic Psychiatry · Harlingen, TX

NPI 1700829215

$1,354.48

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$175.19

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Viiv Healthcare Company $513.89 2019-2023 Dovato
Neurocrine Biosciences, INC. $238.11 2022-2023 Ingrezza
Alkermes, INC. $134.96 2019-2022
Teva Pharmaceuticals USA, INC. $116.68 2019
Sunovion Pharmaceuticals INC. $114.54 2019
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $104.09 2021
Otsuka America Pharmaceutical, INC. $99.49 2019
Gilead Sciences, INC. $32.72 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Cynthia D Rivera

$1,354.48

in general payments reported 2019-2025

Years
2019-2024
Top company
Viiv Healthcare Company

https://glasscript.com/doctor/213521/cynthia-d-rivera

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.